Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know

Core Viewpoint - Twist Bioscience (TWST) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on February 2, with a consensus estimate of a quarterly loss of $0.48 per share, reflecting a year-over-year change of +9.4% [3][11]. - Revenues are projected to reach $101.45 million, which is a 14.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial estimates during this period [4]. - The Most Accurate Estimate for Twist Bioscience is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.05%, suggesting a bearish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from the consensus estimate, with positive readings being more reliable [8][9]. - Twist Bioscience currently holds a Zacks Rank of 2 (Buy), but the negative Earnings ESP complicates predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, Twist Bioscience was expected to post a loss of $0.40 per share but actually reported a loss of $0.45, resulting in a surprise of -12.50% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Industry Comparison - Regeneron (REGN), another player in the biomedical and genetics industry, is expected to report earnings of $10.6 per share for the same quarter, indicating a year-over-year change of -12.2% and revenues of $3.82 billion, up 0.7% from the previous year [17][18]. - Regeneron has an Earnings ESP of +1.06% and a Zacks Rank of 1 (Strong Buy), suggesting a higher likelihood of beating the consensus EPS estimate [19].